Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab beta with induction chemotherapy for newly diagnosed high-risk neuroblastoma
NL-OMON58758Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Dinutuximab beta in neuroblastoma (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Incidence of dose-limiting toxicities. Started Dec 2024; status: recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON58758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58758.